EXACT THERAPEUTICS AS announced that the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) has awarded all necessary approvals to start the dose expansion part of the ACTIVATE study. This part of the ACTIVATE study is designed to determine the dose level for further development and expand the safety and efficacy data of ACT in patients with metastatic colorectal cancer. 12 to 20 patients are planned to be enrolled into the dose expansion part of the ACTIVATE study.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.8 NOK | 0.00% | -2.86% | -43.33% |
1st Jan change | Capi. | |
---|---|---|
-43.33% | 19.75M | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- EXTX Stock
- News EXACT Therapeutics
- EXACT Therapeutics AS Receives Regulatory Approval to Start the Dose Expansion Part of ACTIVATE Study